相关实验视频
Updated: Feb 17, 2026
05:25
Author Spotlight: Enhancing Coronary Artery Revascularization
Published on: September 15, 2023
1.3K
辅助的药理学策略,以减少心肌复血管化后的残留风险
Asahi Oshima1,2, Patrick W Serruys1,2, Scot Garg3,4
1CORRIB Research Centre for Advanced Imaging and Core Laboratory, University of Galway, Galway, Ireland.
概括
动脉样硬化心血管疾病 (ASCVD) 的有效管理涉及降脂疗法和解决残留风险. 新兴的抗炎疗法提供了独立于胆固醇水平的额外好处.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 血管医学 血管医学
背景情况:
- 药物治疗对于治疗动脉样硬化心血管疾病 (ASCVD) 是至关重要的.
- 包括他类药物在内的低密度脂蛋白 (LDL) 降胆固醇疗法在预防心血管事件方面是有效的.
- 新的药物,如埃泽蒂米布,贝佩多酸和PCSK9抑制剂,可以提高LDL的管理能力,特别是在对他类药物不耐受或高风险患者中.
研究的目的:
- 为干预心脏病专家提供ASCVD管理策略的最新概述.
- 总结关于既有和新兴的降脂疗法的证据.
- 讨论抗炎干预在ASCVD中的作用.
主要方法:
- 这是一个叙事评论.
- 它综合了关于ASCVD药理干预的当前证据.
- 该审查侧重于脂质修饰和抗炎方法.
主要成果:
- 已建立的降脂疗法有效减少心血管事件.
- 准剩余脂质风险 (甘油三,脂蛋白,高脂胆固醇) 是一个关键考虑因素.
- 抗炎疗法 (例如,胆固醇,IL-1β抑制剂) 在减少不依赖脂质水平的事件方面表现有前途.
结论:
- 综合性ASCVD管理需要优化LDL胆固醇,解决残留脂质风险,并考虑抗炎策略.
- 进行冠状动脉旁路移植或穿皮冠状动脉干预的医生应该意识到这些不断变化的治疗选择.
- 脂质修饰和抗炎治疗的整合代表了ASCVD护理的重大进步.
相关概念视频
01:27Coronary Artery Disease V: Interprofessional Care
307
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
307
01:28Acute Coronary Syndrome IV: Interprofessional Care
309
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
309
01:25Aortic Regurgitation III: Medical Management
476
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
476
01:26Atherosclerosis III: Management
459
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
459
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.2K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K
01:30Heart Failure V: Medical Management
369
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
369